
Cat. #162125
HEK-AvLigE-A Cell Line
Cat. #: 162125
Availability: 8-10 weeks
Organism: Human
Tissue: Kidney
Disease: Not specific
Model: Genetically modified
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Karine Van Doninck
Institute: Universite Libre de Bruxelle
Primary Citation: Doninck et al. 2023. Nat Commun. Nov 22,14(1):7638. PMID: 37993452
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: HEK-AvLigE-A Cell Line
- Parental cell: HEK293T
- Organism: Human
- Tissue: Kidney
- Disease: Not specific
- Growth properties: Adherent
- Model: Genetically modified
- Description: HEK 293 T expressing the bdelloid ligase AvLigE-A
Handling
- Format: Frozen
- Growth medium: Minimum Essential Medium Eagle (Sigma-Aldrich) supplemented with 10% of Fetal Bovine Serum and 1% of Penicillin/Streptomycin
- Temperature: 37C
- Atmosphere: 5% CO2 in air
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Subculture routine: A subcultivation ratio of 1:3 to 1:8 is recommended
References
- Doninck et al. 2023. Nat Commun. Nov 22,14(1):7638. PMID: 37993452
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)

